Loading…
Employees: 599
Size Wuhan Easy Diagnosis Biomedicine (002932.SZ) is a China Health Care company (Medical Specialties) with a market value of $499M, the 3874th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥14.52 on 6 Nov 2026.
Performance Over six months the shares fell 14.4%, against -9.7% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 9.1% over the last twelve months (peer median +0.7%); the operating margin is -51.2% (peer median 4.4%).
Valuation It trades at 0.57× book value against a peer median of 1.98× (cheapest of 20).
Price implies The share price implies a return on equity of about 3.2%; Wuhan Easy Diagnosis Biomedicine delivers -1.2%, so the price asks more than the business earns today.
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥319M | CN¥265M | CN¥350M | CN¥747M | CN¥10.5B |
| Revenue growth | — | -24% | -53% | -93% | — |
| Gross profit | CN¥165M | CN¥73.3M | CN¥165M | CN¥374M | CN¥6.97B |
| EBITDA | n/a | -CN¥153M | -CN¥70.7M | CN¥92.4M | CN¥5.19B |
| Net income | -CN¥64.0M | -CN¥16.5M | CN¥74.5M | CN¥74.9M | CN¥4.21B |
| Free cash flow | CN¥205M | -CN¥93.6M | -CN¥252M | CN¥317M | CN¥3.74B |
| Capital expenditure | CN¥55.5M | CN¥90.9M | CN¥185M | CN¥110M | CN¥313M |
| Total debt | CN¥32.7M | CN¥9.72M | CN¥13.1M | CN¥49.2M | CN¥220M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002932.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -4.3% | 9th lowest of 21 |
| 6-month return | -14.4% | -9.7% | 9th lowest of 21 |
| Return on equity | -1.2% | 1.8% | 6th lowest of 20 |
| Price / book | 0.57× | 1.98× | cheapest of 20 |
| ROE the price implies | 3.2% | 14.3% | least demanding of 20 |
| ROE delivered | -1.2% | 1.7% | 6th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -1% | 0.57× | 3.2% | -1.2% |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 10% | 2.44× | 14.8% | 10.4% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -19% | 3.04× | 13.2% | -19.2% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 2% | 1.77× | 9.5% | 1.8% |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | n/a | n/a | n/a | n/a |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 15% | 5.09× | 21.0% | 15.5% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -9% | 2.29× | 20.6% | -8.5% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -2% | 1.98× | 14.3% | -1.6% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | 0% | 4.27× | 24.1% | 0.5% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.10× | 19.3% | -9.1% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 6% | 0.64× | 6.0% | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 3% | 0.88× | 5.6% | 3.0% |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 13% | 1.47× | 7.1% | 13.2% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 8% | 1.12× | 9.7% | 8.4% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 2% | 0.63× | 4.8% | 1.8% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | -44% | 3.64× | 17.4% | -44.2% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 2% | 2.51× | 22.6% | 2.0% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | 4.59× | 42.6% | 1.6% |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 4% | 0.87× | 17.6% | 4.0% |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 0% | 1.02× | 6.5% | 0.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 1% | 1.46× | 12.7% | 1.1% |